NDATOPICALCREAM
Approved
Feb 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SSD AF (silver sulfadiazine) by Dr. Reddy's Laboratories is clinical pharmacology silver sulfadiazine has broad antimicrobial activity. First approved in 1982.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SSD AF is a topical cream formulation of silver sulfadiazine, a broad-spectrum antimicrobial agent indicated for burn wound management. It acts bactericidally on the cell wall, demonstrating efficacy against gram-negative and gram-positive bacteria as well as Candida species, including organisms resistant to other antimicrobial agents.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); team size likely stable or contracting as generic entry accelerates.
Mechanism of Action
CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below. Sufficient data have been obtained to demonstrate that silver…
Pharmacologic Class:
Sulfonamide Antibacterial
Indications
Worked on SSD AF at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.